Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Think the market starts very green this week?
Anyone else get this email? What are we thinking?
"The UCLA Brain Tumor Center is pleased to announce Part Two of the UCLA Brain Tumor Virtual Conference. This online event will take place on Friday, March 12th from 10:00am to 5:00pm
Join us at our online educational meeting to learn about brain tumor symptom management, nutrition, and clinical trials. We will also have a Q&A Panel with all participating speakers, giving attendees the opportunity to ask questions they may have. This event is free and open to all, but registration is required."
Market prediction tomorrow? I got crushed today
Laughing so hard at that image
LC check here for link, made a YouTube for ya:
Agreed Bio, this Advent update is a huge breadcrumb including the screenshots that I just posted of 5 people specializing in the production of DCVax. We got this you guys.
Let me quiet all you naysayers down. The position that flipper44 posted, now has 5 people in the same roles and their job description is specifically to work on DCVax.
Sharing screenshots if I can figure out how.
https://photos.app.goo.gl/TDm2jgzw1vnaZxoB7
https://photos.app.goo.gl/SAjqyHWg66yNH6u17
https://photos.app.goo.gl/NHyR9U6bNuxqFsUC8
https://photos.app.goo.gl/hGW6t6BDrERVmswz9
Also, this talks directly about the trial:
"It is notable that the three largest RCTs initiated to date have faced huge logistic/financial problems, as follows: (1) The EudraCT 2009-018228-14 trial aimed to include 146 study objects but was abruptly closed by the sponsor after the inclusion of 135 patients. The reasons for this were kept confidential. Nevertheless, the scientific data were made available, were extremely well-documented, and were partially transferred onto the platform of the EU Project Computational Horizons in Cancer (www.chic-vph.eu). Data on 132 patients were finally brought into a new study, named the Glioma Translat Study, and published [166,167]; (2) NCT00045968 was designed to include 348 study objects with PFS as the primary read-out and OS as the secondary read-out. Eighty sites in four countries were used for recruitment. The study screened 1268 patients and ended up with 331 randomizations into the main study [160]. Patient recruitment was initiated in 2007 but was paused from 2009 to 2011 for economic reasons. The final patient was enrolled in November 2015. This resulted in a recruitment period of nine years, an effective inclusion period of six years, and a mean of four patients per recruiting site at an effective rate of less than one patient per year per site. Five years later, at the time of writing, the final results regarding the randomized data collected on these patients and the answer to the primary question (PFS) have not yet been published; (3) NCT02546102 suspended further patient randomization due to financial reasons [168]. It is not clear how many patients had already been recruited into the trial."
Stumbled across this article.. has this been shared before?
https://www.mdpi.com/2072-6694/13/1/32/htm#B164-cancers-13-00032
A lot of good information in here, confirming the efficacy of dendritic cell vaccinations... And I believe a lot of the information is based on nwbio trial.
This is great evidence here.. And the reference links to LM Liau :
"In the design of larger RCTs with a control arm, clinical researchers have run into new problems. GBM is a deadly disease. The first interest of the patient is the prolongation of a good-quality life. As DC vaccination has already been shown to significantly prolong long-term OS with a good quality of life, it eventually became unethical to prevent patients in the control arm from being given this innovative fourth anti-GBM immunotherapy modality. Therefore, some RCTs published with PFS as the primary endpoint used a cross-over protocol from the control group to the DC vaccination group, either structurally within the trial design (EudraCT 2009-018228-14) [151] or after reaching the primary end-point (NCT00045968) [160]. By doing so, the OS assessment was, in fact, no longer controlled. In the former study, stratification of RPA classification was used. In the latter study, stratification for MGMT methylation was used."
Hey basin, it's more just very interesting information on how the vaccine actually works and it's effectiveness. It's crazy how much information they've learned and how untapped the potential of this treatment is. If effective as it looks, it's truly going to be world changing... And I'm not sure to what extent everyone genuinely understands that.
Some really interesting details that I haven't read in detail before here: https://patentscope.wipo.int/search/en/detail.jsf?docId=US237388322&tab=PCTDESCRIPTION
Yes! I literally just found it and came back to post here: https://patentscope.wipo.int/search/en/detail.jsf?docId=US237388322&tab=NATCOLLDOCUMENTS
Thank you 10B. I'm reading to look at this again and it looks like it's moved forward potentially? Digging more, but does anyone have any idea on relevance here?
For the past couple of days I've been trying to dig up a link that someone shared here a couple months back relating to an approval submission that was in progress. It wasn't anything FDA related or any sort of drug approval. I can't recall what it was specifically, maybe a trade mark or something of that nature. I know it was a government website. It may have been ATL or bio or Poor man (or neither) who shared the link.
Does that ring a bell for anyone? Either way I'll keep digging and share when I find my brain.
Welcome back thermo
Love this one.
Great article. Thanks for sharing!
I am with you on this. The PR statement CR issued practically spells it out.
Doc, thank you so much for the additional clarity here. That makes a lot more sense to me.
Appreciate your time.
Hi Doc - Can you summarize? I'm not sure I fully comprehend the point you are making here.
Are you saying that this is should not be considered a clue towards positive data of DCVax?
Drugrunner - while this doesn't explicitly state NWBO, the line I've highlighted below from the press release that JRIII is calling out is very likely to be NWBO considering all of the other facts we know.
"The HQ plasmid manufacturing service provides a rapid six-week delivery time for the clinical manufacture of immuno-oncology therapies"
Here is the URL as well: https://www.biospace.com/article/releases/cognate-bioservices-announces-major-expansion-of-manufacturing-facilities-in-us-and-europe/
There are only a few immuno-oncology therapies that I'm aware of, and only one that truly fits the narrative here. Any one else that can add any color here?
I know this is a stretch and a lot of people have already said this but it reads to me as that the Q could be late due to acquisition or some other substantial change to the company.
Where are you getting this?
I'm going to go out on a limb to bet that tomorrow we may get up listing news. 90 days over $1 marks tomorrow. Who wants to take the bet?
Love you Thermo.. thanks for the update.
-Long time lurker